- Conatus Pharmaceuticals (CNAT) flies in early trading after the company discloses that Novartis exercised a license for the development and commercialization of Emricasan.
- The company now believes that it has the financial resources to maintain operations and ongoing clinical development activities through the end of 2019.
- CNAT +12.95% premarket to $9.16 vs. a 52-week trading range of $1.45 to $9.40.
Conatus Pharma up after Novartis exercises option
Recommended For You
About HSTO Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
HSTO | - | - |
Histogen Inc. |